Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2023 Apr;39(4):533-543.
doi: 10.1080/03007995.2023.2178148. Epub 2023 Feb 20.

Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumab

Maryia Zhdanava  1 , Zhijie Ding  2 , Ameur M Manceur  1 , Erik Muser  2 , Patrick Lefebvre  1 , Christopher Holiday  1 , Marie-Hélène Lafeuille  1 , Dominic Pilon  1
Affiliations
Comparative Study

Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumab

Maryia Zhdanava et al. Curr Med Res Opin. 2023 Apr.

Abstract

Objectives: To compare persistence and describe dose titration among bio-naïve patients with Crohn's disease (CD) initiated on ustekinumab or adalimumab.

Methods: Bio-naïve adults with CD who initiated ustekinumab or adalimumab (index date) from 23 September 2016 (ustekinumab US approval for CD) to 1 August 2019 were selected from IQVIA PharMetrics Plus. Cohorts were balanced on baseline characteristics measured over 12 months pre-index using inverse probability of treatment weights. Persistence was defined as no gaps (ustekinumab: >120 days; adalimumab: >60 days) between days of supply. Dose escalation was defined as ≥2 consecutive sub-cutaneous claims 100% above the US label daily dose in the maintenance phase; de-escalation was a return to the daily dose for ≥2 consecutive claims. Outcomes were described using weighted Kaplan-Meier models; persistence outcomes were compared using Cox's proportional hazards models.

Results: At 12 months post-index, patients in the ustekinumab (n = 948) versus adalimumab (n = 4143) cohort had a significantly higher rate of persistence on index biologic (hazard ratio [HR] 1.50; 95% confidence interval [CI]: 1.29-1.74). A total of 830 (87.6%) patients in the ustekinumab cohort and 3713 (89.6%) in the adalimumab cohort began the maintenance phase; within 12 months, 11.2% and 16.9%, underwent a dose escalation, and 26.6% and 6.3%, respectively, subsequently de-escalated to the per US label daily exposure.

Conclusions: Bio-naïve patients with CD initiated on ustekinumab were more persistent than patients initiated on adalimumab; moreover, these patients had numerically lower dose escalation and higher de-escalation rates than patients initiated on adalimumab. Findings support the use of ustekinumab as a first-line treatment for bio-naïve patients with CD.

Keywords: Crohn’s disease; biologics; clinical pharmacology; compliance/adherence; inflammatory bowel disease; outcomes research.

PubMed Disclaimer

Publication types

LinkOut - more resources